Geron: Opportunity Builds Even As Struggles Continue (NASDAQ:GERN)
· seekingalpha.com
Geron achieved FDA approval for RYTELO in June 2024, targeting lower-risk myelodysplastic syndromes. Read what makes GERN stock a compelling Buy.
This is my latest in a long series of Geron ( GERN ) articles dating back to 04/2017. In the early days, investors were on tenterhooks to see whether Johnson & ...